Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2007.3.6 | Award Amount: 4.33M | Year: 2008
The key objective of ULTRAsponder is to develop a novel telemetry technology for biomedical applications that will enable any kind of deeply implanted device (the transponder) to communicate and be powered wirelessly via acoustic waves with the external system (the control unit). The implanted transponder will include one or more sensors for monitoring a variety of parameters, such as temperature, pressure, or fluid flow. Local digital signal processing will allow the transponder to act smartly and transmit only significant data, reducing its power needs. As part of a network, several transponders will communicate and exchange information with the external control unit. The control unit will be placed on the patients skin, and it will control, energize and communicate through acoustic waves (ultrasonic) with the implanted transponders. Moreover, it will be used as a data logger, which relays the recorded data from the transponders network, towards the patients environment via cellular, plain telephone service (POTS) or IP based networks.The key innovations of ULTRAsponder will be the following: (i) development of a novel telemetry technique based on the backscattering principle to ensure efficient data communication through acoustic waves from the implanted transponder to the external control unit, (ii) wireless communication through acoustic waves from the control unit to the transponder, (iii) remote powering of the transponder through acoustic waves using a beam-forming technique to increase efficiency and hence to reduce charge time (iv) internal pre-treatment of the sensor measurements thanks to local massive and low power signal processing capabilities, (v) high flexibility and modularity of the transponder to be easily adaptable to any kind of sensor, (vi) test of the overall system in real environment for a particular application to measure physiological parameters, (vii) contribution to the standardization of body sensor networks using acoustic waves
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-29-2016 | Award Amount: 5.11M | Year: 2017
X-ray mammography is the mainstay of breast cancer screening programs. It is estimated that between 20 - 50% of abnormal screening mammograms will prove to be negative. The paradigm in diagnosis is to establish whether a lesion is benign or malignant. All the imaging techniques conventionally used today diagnostic x-ray, ultrasonography and magnetic resonance imaging have many limitations, leading to multiple and/or repeat imaging and often unnecessary biopsy. This leads to physical, psychological and economic burdens felt at individual, familial and societal levels. With an aging population, high incidence of breast cancer and tightening health-care budgets, there is an urgent requirement for a non-invasive method for in-depth assessment of the screening-detected lesion. In PAMMOTH we will showcase such an imager, combining photoacoustic and ultrasound imaging. With the use of quantitative image reconstruction of multi-wavelength photoacoustic data, information is gained of the vascular and oxygen status of the lesion relating to tumor physiology and function. From the ultrasound part, we derive ultrasound reflection from the lesion in a manner superior to conventional breast ultrasonography, relating to anatomic features and extent of a tumor. This information will enable the radiologist to come to a diagnosis accurately and rapidly without the use of contrast agents, without pain and discomfort to the patient, while being cost-effective and not requiring complex infrastructure. Four excellent academic groups, three dynamic SMEs, and a hospital come together with support from key stakeholders in an Advisory group, to push beyond the state-of-the-art in science and technology to achieve the PAMMOTH imager. For the SMEs, in addition to tremendous improvements in individual product lines, the new integrated diagnostic imaging instrument opens up completely new market opportunities. We expect PAMMOTH to have a strong economic and clinical impact.
Mari J.-M.,University of Lyon |
Bouchoux G.,University of Lyon |
Dillenseger J.-L.,University of Rennes 1 |
Gimonet S.,IMASONIC S.A.S |
And 8 more authors.
IRBM | Year: 2013
The development of endocavitary dual-mode probes is essential for the accurate treatment of many deep-seated cancers, which require a high imaging resolution and the capacity to selectively treat focal areas in the region of interest. The MULTIP project is aimed at using state-of-art piezoelectric technologies to design dual-mode ultrasonic probes for cancer-foci treatment and monitoring. In order to allow an efficient surgery planning, the technical study has been accompanied by a volume processing study permitting the design of the ultrasonic imaging/therapy process based on high-resolution-high-quality MRI images. Several prototypes were designed based on a simulation study and implemented: 1) two successive wide-band dual-mode transducer allowing imaging at high-resolution (6 MHz) on a wide field of view, and therapy at 3 MHz with a good transduction efficiency (48% and 70%); 2) a therapy-only transducer matrix adapted to the desired curvature with a high transduction efficiency (70%). Finally, a registration study of MRI volumes on ultrasound volumes has shown that, because of the texture of the ultrasound images, it is more efficient to search at registering the surfaces of the volumes once they have been segmented in each modality, rather than trying to register the two data volumes directly. © 2013 Elsevier Masson SAS.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 8.61M | Year: 2014
The aim of the iPaCT project is to address the unmet clinical need for an improved therapy of pancreatic cancer by developing a new integrated technology platform for image-guided thermal therapy. Yearly, 280000 new cases of pancreatic cancer are diagnosed worldwide. Being usually diagnosed late stage and without any efficient therapy available, basically all patients die with an average life expectancy of only a few months after diagnosis, leading to an overall low prevalence in society. Therefore, pancreatic cancer is a rare disease with an urgent clinical need for a new and improved therapeutic option. A potential breakthrough solution for the treatment of pancreatic cancer can be found in thermal therapies using high intensity focused ultrasound (HIFU) combined with local, temperature-triggered drug delivery. We propose a novel US-MR-HIFU system that integrates HIFU with two imaging modalities, i.e. Magnetic Resonance Imaging (MRI) and diagnostic Ultrasound (US) for image guidance of thermal ablation (T=60C) and/or hyperthermia (T=42-43C) of pancreatic tumours. For image-guided drug delivery, new temperature-sensitive nanocarriers will be developed that provide a high local dose of chemotherapeutic drug. Multimodal (molecular) imaging information, simultaneously acquired using the US-MR-HIFU platform, provides motion compensated temperature feedback as well as visualization of perfusion and drug uptake in the target tissue allowing personalized therapy. The consortium, including two innovative SMEs (Imasonic, Neagen), two hospitals (Klinikum der Universitt Mnchen and University Medical Center Utrecht), Eindhoven University of Technology and Philips (a medical device company), represents the total chain from technology development, preclinical testing to clinical translation guaranteeing a clear route for later clinical use and a route to market for the SMEs partners, leveraging the competencies and strengths of a leading global healthcare company.
Denis De Senneville B.,University of Bordeaux Segalen |
Ries M.,University of Bordeaux Segalen |
Quesson B.,University of Bordeaux Segalen |
Trillaud H.,Bordeaux University Hospital Center |
And 3 more authors.
IRBM | Year: 2011
Objective: Thermal therapies are rapidly gaining importance in oncology as an alternative to radiotherapy and surgery. The possibility to locally deposit thermal energy in a non-invasive way opens a path towards new therapeutic strategies with improved reliability and reduced associated trauma leading to improved efficacy, reduced hospitalisation and costs. Liver and kidney tumors represent a major health problem because not all patients are suitable for curative treatment with surgery. Currently, radiofrequency is the most used method for percutaneous ablation and the development of a completely non-invasive method based on MR-guided high intensity focused ultrasound (HIFU) treatments is of particular interest, since the energy source is located outside the body. This project addressed technological challenges for the treatment of liver and kidney, related to their motion and their location within the thoracic cage. Material and methods: This project proposed safe and non-invasive methods for MR-guided thermal ablation of malignant tumors of liver and kidney with HIFU. Real-time MRI was used to precisely control heat deposition with HIFU within the targeted pathological area despite the motion of these organs, in order to provide an effective treatment with a reduced duration and an increased level of safety for the patient. New technologies were studied for the development of matrix transducers able to generate high acoustic power. Discussion: 3D Real-Time MRI guidance of a HIFU intervention as well as intercostal firing were realized in vivo in pig liver during breathing under real-time MR-thermometry over sustained periods of several minutes. The ability to generate acoustic power as high as up to five time the usual level was demonstrated in vitro thanks to the development of the new transducer technology proposed in this project. Conclusion: A fully MR-integrated HIFU treatment platform dedicated to the treatment of cancer in mobile abdominal organs was developed. © 2011 Elsevier Masson SAS. All rights reserved.
Owen N.R.,French Institute of Health and Medical Research |
Chapelon J.Y.,French Institute of Health and Medical Research |
Chapelon J.Y.,University of Lyon |
Bouchoux G.,French Institute of Health and Medical Research |
And 4 more authors.
Ultrasonics | Year: 2010
Medical imaging is a vital component of high intensity focused ultrasound (HIFU) therapy, which is gaining clinical acceptance for tissue ablation and cancer therapy. Imaging is necessary to plan and guide the application of therapeutic ultrasound, and to monitor the effects it induces in tissue. Because they can transmit high intensity continuous wave ultrasound for treatment and pulsed ultrasound for imaging, dual-mode transducers aim to improve the guidance and monitoring stages. Their primary advantage is implicit registration between the imaging and treatment axes, and so they can help ensure before treatment that the therapeutic beam is correctly aligned with the planned treatment volume. During treatment, imaging signals can be processed in real-time to assess acoustic properties of the tissue that are related to thermal ablation. Piezocomposite materials are favorable for dual-mode transducers because of their improved bandwidth, which in turn improves imaging performance while maintaining high efficiency for treatment. Here we present our experiences with three dual-mode transducers for interstitial applications. The first was an 11-MHz monoelement designed for use in the bile duct. It had a 25 × 7.5 mm2 aperture that was cylindrically focused to 10 mm. The applicator motion was step-wise rotational for imaging and therapy over a 360°, or smaller, sector. The second transducer had 5-elements, each measuring 3.0 × 3.8 mm2 for a total aperture of 3.0 × 20 mm2. It operated at 5.6 MHz, was cylindrically focused to 14 mm, and was integrated with a servo-controlled oscillating probe designed for sector imaging and directive therapy in the liver. The last transducer was a 5-MHz, 64-element linear array designed for beam-formed imaging and therapy. The aperture was 3.0 × 18 mm2 with a pitch of 0.280 mm. Characterization results included conversion efficiencies above 50%, pulse-echo bandwidths above 50%, surface intensities up to 30 W / cm2, and axial imaging resolutions to 0.2 mm. The second transducer was evaluated in vivo using porcine liver, where coagulation necrosis was induced up to a depth of 20 mm in 120 s. B-mode and M-mode images displayed a hypoechoic region that agreed well with lesion depth observed by gross histology. These feasibility studies demonstrate that the dual-mode transducers had imaging performance that was sufficient to aid the guidance and monitoring of treatment, and could sustain high intensities to induce coagulation necrosis in vivo. © 2009.